Cargando…

Orbital Exenteration in Recurrence Cancer: 5 Years Experience

Introduction: The purpose of this study was to assess the overall survival (OS) and disease-free survival (DFS) of patients who underwent orbital exenteration for periorbital, conjunctival, and primary intraorbital carcinomas. Additionally, we assessed the outcomes of anterior retrograde temporalis...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbera, Giorgio, Todaro, Mattia, Saponaro, Gianmarco, Gasparini, Giulio, Moro, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573591/
https://www.ncbi.nlm.nih.gov/pubmed/37834824
http://dx.doi.org/10.3390/jcm12196180
_version_ 1785120499912671232
author Barbera, Giorgio
Todaro, Mattia
Saponaro, Gianmarco
Gasparini, Giulio
Moro, Alessandro
author_facet Barbera, Giorgio
Todaro, Mattia
Saponaro, Gianmarco
Gasparini, Giulio
Moro, Alessandro
author_sort Barbera, Giorgio
collection PubMed
description Introduction: The purpose of this study was to assess the overall survival (OS) and disease-free survival (DFS) of patients who underwent orbital exenteration for periorbital, conjunctival, and primary intraorbital carcinomas. Additionally, we assessed the outcomes of anterior retrograde temporalis muscle flap restoration. Methods: For all patients who had orbital exenteration in the previous five years, a non-comparative retrospective assessment of their medical records, histology, and radiographic imaging was carried out. We investigated the relationships between the various qualitative factors using Cramer’s V Kaplan–Meier (KM) analysis. For each of the patient’s categorical factors that were of relevance, estimates of the survival distribution were displayed, and log-rank tests were used to determine whether the survival distributions were equal. Results: This study looks at 19 participants. The sample is made up of 13 men (68%) and 6 women (32%). The degree of relationship (Cramer’s V index) between lymph node metastases (N) and the existence of distant metastases (M) is high, at 64%, and is statistically significant because the p-value is 0.0034 < 0.005. Lymph node metastases had a statistically significant impact on overall survival (p = 0.04 < 0.05). Thirteen of the nineteen patients tested had no palsy (68%). There was no one presenting a CSF leak. Conclusion: Our findings show how crucial it is to identify any lymph node involvement that orbital neoplasms may have. In patients who have received many treatments, sentinel lymph node biopsy (SLNB) may be used to determine the stage and spread of the cancer. To determine whether additional tumor characteristics may be explored, more expertise in the SLNB field for patients with orbital cancer who have received many treatments may be helpful. To prevent additional scarring and to be comparable to previous techniques for facial nerve lesions, the anterior retrograde approach and the transorbital procedure for temporal muscle flap in-setting are both effective methods.
format Online
Article
Text
id pubmed-10573591
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105735912023-10-14 Orbital Exenteration in Recurrence Cancer: 5 Years Experience Barbera, Giorgio Todaro, Mattia Saponaro, Gianmarco Gasparini, Giulio Moro, Alessandro J Clin Med Article Introduction: The purpose of this study was to assess the overall survival (OS) and disease-free survival (DFS) of patients who underwent orbital exenteration for periorbital, conjunctival, and primary intraorbital carcinomas. Additionally, we assessed the outcomes of anterior retrograde temporalis muscle flap restoration. Methods: For all patients who had orbital exenteration in the previous five years, a non-comparative retrospective assessment of their medical records, histology, and radiographic imaging was carried out. We investigated the relationships between the various qualitative factors using Cramer’s V Kaplan–Meier (KM) analysis. For each of the patient’s categorical factors that were of relevance, estimates of the survival distribution were displayed, and log-rank tests were used to determine whether the survival distributions were equal. Results: This study looks at 19 participants. The sample is made up of 13 men (68%) and 6 women (32%). The degree of relationship (Cramer’s V index) between lymph node metastases (N) and the existence of distant metastases (M) is high, at 64%, and is statistically significant because the p-value is 0.0034 < 0.005. Lymph node metastases had a statistically significant impact on overall survival (p = 0.04 < 0.05). Thirteen of the nineteen patients tested had no palsy (68%). There was no one presenting a CSF leak. Conclusion: Our findings show how crucial it is to identify any lymph node involvement that orbital neoplasms may have. In patients who have received many treatments, sentinel lymph node biopsy (SLNB) may be used to determine the stage and spread of the cancer. To determine whether additional tumor characteristics may be explored, more expertise in the SLNB field for patients with orbital cancer who have received many treatments may be helpful. To prevent additional scarring and to be comparable to previous techniques for facial nerve lesions, the anterior retrograde approach and the transorbital procedure for temporal muscle flap in-setting are both effective methods. MDPI 2023-09-25 /pmc/articles/PMC10573591/ /pubmed/37834824 http://dx.doi.org/10.3390/jcm12196180 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Barbera, Giorgio
Todaro, Mattia
Saponaro, Gianmarco
Gasparini, Giulio
Moro, Alessandro
Orbital Exenteration in Recurrence Cancer: 5 Years Experience
title Orbital Exenteration in Recurrence Cancer: 5 Years Experience
title_full Orbital Exenteration in Recurrence Cancer: 5 Years Experience
title_fullStr Orbital Exenteration in Recurrence Cancer: 5 Years Experience
title_full_unstemmed Orbital Exenteration in Recurrence Cancer: 5 Years Experience
title_short Orbital Exenteration in Recurrence Cancer: 5 Years Experience
title_sort orbital exenteration in recurrence cancer: 5 years experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573591/
https://www.ncbi.nlm.nih.gov/pubmed/37834824
http://dx.doi.org/10.3390/jcm12196180
work_keys_str_mv AT barberagiorgio orbitalexenterationinrecurrencecancer5yearsexperience
AT todaromattia orbitalexenterationinrecurrencecancer5yearsexperience
AT saponarogianmarco orbitalexenterationinrecurrencecancer5yearsexperience
AT gasparinigiulio orbitalexenterationinrecurrencecancer5yearsexperience
AT moroalessandro orbitalexenterationinrecurrencecancer5yearsexperience